Scope, Claims, and US Patent Landscape for US 8,252,329 (Sufentanil Bioadhesive Sublingual Tablet)
US 8,252,329 claims a tightly defined bioadhesive tablet for oral transmucosal (sublingual) sufentanil delivery. The claim set centers on four enforced pillars: (1) dose (microgram-range sufentanil, expressed as base), (2) bioadhesive composition (weight fraction and adhesion performance), (3) tablet physical form/behavior in saliva (hydrogel vs non-hydrogel eroding vs film/disintegration; dissolution independence from pH), and (4) in-vivo or functional delivery outcomes (minimal saliva response and swallowing; and at least 55% of delivered sufentanil via oral transmucosal route). Dependent claims lock in specific application and device systems (SDA/syringe, placement accuracy, dryness prior to dispensing, lockout/ID control) and specific formulation/excipients (notably crosslinked sodium carboxymethylcellulose) and performance metrics (bioavailability >70%, attachment force window, disintegration time window, thickness/volume ranges).
What is the core invention scope in claim 1?
Independent claim 1: what it covers
Claim 1 recites a bioadhesive tablet for sublingual administration comprising:
- Drug:
- “from about 2.5 to about 100 micrograms of sufentanil, expressed as the base”
- Bioadhesive material:
- present at “2-30% by weight”
- provides “adherence to the oral mucosa”
- Tablet volume constraint:
- “volume of from about 0.1 microliters to about 50 microliters”
- Delivery behavior / functional outcome constraints:
- after administration, “provides a minimal saliva response and minimal swallowing of sufentanil”
- “at least 55% of drug delivery of sufentanil occurs via the oral transmucosal route”
These elements make claim 1 both composition-limited and performance-limited. A design-around must avoid at least one of the enumerated constraints (dose band, bioadhesive loading band, tablet volume band, or the oral transmucosal delivery/behavior thresholds).
What “oral transmucosal route” threshold does
The claim requires that:
- ≥55% of delivered sufentanil occurs via the oral transmucosal route (not swallowed and absorbed systemically via GI).
That threshold can become the decisive metric in infringement analysis when formulations deliver drug but with different absorption pathways.
What does claim 1 force competitors to match on formulation behavior?
Claim 1 is followed by multiple dependent claims that narrow how the tablet behaves on contact with aqueous fluid (saliva/water). Together, they create multiple “variant embodiments” that are each claim-anchored.
Hydrogel embodiment (claim 2)
- Tablet “becomes a hydrogel upon contact with an aqueous fluid.”
Eroding (non-hydrogel) embodiment (claim 3)
- Tablet is an “eroding tablet”
- hydrates and erodes “without formation of a hydrogel.”
Disintegrates/film formation embodiment (claim 4)
- On contact with aqueous fluid, tablet “disintegrates and forms a film.”
pH-independent dissolution (claims 5-6)
- Dissolution “independent of pH”
- further limited: independent of pH “over a pH range of about 4 to 8.”
Landscape implication: If an accused product uses a pH-dependent matrix, dissolution that shifts sharply outside pH 4-8 can undercut this dependent claim route, but claim 1 itself does not explicitly require pH independence. pH independence is only enforced in dependent claims.
What devices and delivery systems are covered (SDA, placement, lockout)?
Single dose applicator (claim 7)
- “A single dose applicator (SDA) comprising a tablet according to claim 1”
- where SDA is a “syringe.”
This captures systems beyond just the tablet composition.
Drug dispensing device with ID/lockout (claim 8)
- “A drug dispensing device comprising the tablet”
- effective to “check user identification” and “provide a lockout period between dose dispenses.”
This is a systems/controls limitation layered onto the tablet claim.
Placement accuracy and dryness in device (claims 21-24, 23-24)
- SDA/device is “effective to accurately place said tablet in the sublingual space/area”
- tablet “remains dry in said SDA/device prior to dispensing”
- a “single tablet is dispensed” into the mouth.
These features are practical points for infringement: many alternate delivery approaches (push-through blister, wafer-in-mouth, dissolvable film on a carrier) could be argued not to satisfy “dryness prior to dispensing” or “accurate placement” if claim construction allows.
User interface and data transfer (claim 25)
- device has a “user interface” where “dosage history can be transferred to another device, computer or network.”
This is broad enough to cover telehealth monitoring and secure dose logging within the dispensing workflow.
What are the quantified formulation ranges that define infringement boundaries?
Claim 1 contains the broad volume band; dependent claims narrow the volume and thickness; others define adhesion and disintegration.
Tablet volume dependent ranges (claims 9-11)
- claim 9: 0.5 to 10.0 microliters
- claim 10: 1.0 to 25 microliters
- claim 11: 3.0 to 15.0 microliters
Note: all depend on claim 1’s volume concept. A product within one of these bands can align with those dependent claims even if it misses others.
Dose-specific dependent claims (claims 12-13)
- claim 12: 10 micrograms sufentanil (base)
- claim 13: 15 micrograms sufentanil (base)
These are high-value enforcement targets because many marketed dose strengths cluster tightly.
Thickness dependent claim (claim 14)
Disintegration time dependent claim (claim 15)
- disintegrates over 10 to 30 minutes after sublingual administration.
Attachment force dependent claim (claim 26)
- attachment force: 0.03 to 0.18 N/cm² to a porcine mucosa substrate in vitro.
This is a specific measurable property. If a rival matrix increases or decreases adhesion outside this window, it can avoid this dependent claim even if it still delivers with high transmucosal fraction.
What performance thresholds matter most for oral transmucosal delivery and bioavailability?
Oral transmucosal delivery threshold (claim 1)
- ≥55% of delivered sufentanil via oral transmucosal route
This is the central pharmacokinetic gateway.
Minimal saliva response and minimal swallowing (claim 1)
This is a functional behavior constraint tied to administration outcomes:
- minimal saliva response
- minimal swallowing of sufentanil
This can be difficult to prove without study data, but it gives the patentee an infringement narrative: the formulation is tuned for retention and transmucosal absorption.
Bioavailability dependent claim (claims 16 and 20)
- “bioavailability of greater than 70%” with single or repeated oral transmucosal administration.
Claims 16 and 20 are substantively aligned, reinforcing that high bioavailability is an expected performance signature.
Excipients tied to disintegration kinetics and drug release (claims 17-18)
- tablet further comprises excipients affecting:
- disintegration kinetics and drug release
- specifically: crosslinked sodium carboxymethylcellulose
This introduces a mechanistic formulation hook. A rival using a different polymer system can avoid these dependent claims while still possibly meeting claim 1 if all other elements align (dose band, bioadhesive % band, volume, and functional oral transmucosal fraction).
What is the practical claim chart: scope by “coverage axis”?
Coverage axis 1: Drug dose and drug identity
- Sufentanil identity is required.
- Dose band: 2.5 to 100 micrograms (base).
Coverage axis 2: Tablet size and geometry
- Volume: 0.1 to 50 microliters (claim 1)
- Dependent volume bands:
- Thickness: 0.5 to 3.0 mm
Coverage axis 3: Bioadhesive composition and loading
- Bioadhesive weight: 2-30%
- Dependent adhesion performance: 0.03-0.18 N/cm² (porcine mucosa in vitro)
Coverage axis 4: Behavior in saliva (contact with aqueous fluid)
- hydrogel formation (claim 2)
- eroding without hydrogel (claim 3)
- disintegrate and form film (claim 4)
Coverage axis 5: Dissolution mechanism
- dissolution pH independence (claim 5), especially pH 4-8 (claim 6)
Coverage axis 6: Delivery outcome (pharmacokinetic/physiology)
- ≥55% transmucosal route (claim 1)
- minimal saliva response and minimal swallowing (claim 1)
- bioavailability >70% (claims 16/20)
Coverage axis 7: Device system
- SDA as syringe (claim 7)
- placement accuracy (claims 21, 23)
- tablet remains dry pre-dispense (claims 22, 24)
- lockout and ID control (claim 8)
- UI for dose history transfer (claim 25)
How does this claim structure shape the patent landscape for competitors?
1) The patent is not only a formulation patent
It expands into device and dispensing workflow controls:
- ID/lockout systems
- placement accuracy and dryness handling
- syringe-based SDA
- dose history transfer UI
This increases exposure for companies building the administration mechanism, not just the tablet.
2) The performance-limited claim 1 can capture “different excipients” if delivery thresholds match
Even if a rival uses a different polymer than crosslinked sodium carboxymethylcellulose, it can still fall within claim 1 if:
- it uses sufentanil dose within range,
- uses bioadhesive at 2-30% by weight,
- uses a tablet with volume in range,
- and achieves the functional oral transmucosal outcome (≥55%) and minimal saliva/swallowing behavior.
3) Dependent claims create multiple “entry points” for enforcement
A competitor may avoid claim 1 by missing one core element, but still be hit by dependent-claim alignment if they satisfy those narrower conditions. Typical high-risk intersections:
- marketed strengths at 10 or 15 micrograms
- device implementation as dry syringe SDA
- adhesion force within 0.03-0.18 N/cm²
- disintegration time 10-30 minutes
- polymer choice: crosslinked sodium carboxymethylcellulose
What are the main infringement scenarios and design-around levers?
Infringement scenario A: dose-range + bioadhesive loading + transmucosal fraction
A tablet delivering ≥55% via oral transmucosal route and showing minimal saliva/swallowing can be captured even if tablet gelling erodes differently (hydrogel vs eroding vs film), since claim 1 does not force a single saliva behavior. Dependent claims will then determine additional coverage.
Design-around levers:
- shift delivery pathway below the ≥55% threshold
- modify composition such that bioadhesive is outside 2-30% by weight
- change tablet volume outside 0.1-50 microliters
- change dose outside 2.5-100 micrograms
Infringement scenario B: device-based SDA coverage
If a competitor uses a syringe-type SDA that keeps a tablet dry and accurately places it sublingually, then device/system claims become a parallel exposure channel.
Design-around levers:
- non-syringe SDA architecture
- pre-hydrated or carrier-based administration that does not meet “remains dry” limitation as claim construed
- alternative placement mechanism that challenges “accurately place” limitation
Infringement scenario C: dependent-claim specific materials and performance
If a formulation uses crosslinked sodium carboxymethylcellulose and hits the adhesion and disintegration windows, it aligns strongly with multiple dependent claims.
Design-around levers:
- change excipient system away from crosslinked sodium carboxymethylcellulose
- tune adhesion force outside 0.03-0.18 N/cm²
- adjust disintegration time outside 10-30 minutes
- tune thickness outside 0.5-3.0 mm
Key Takeaways
- US 8,252,329 centers on sufentanil bioadhesive sublingual tablets with enforced ranges for dose (2.5-100 micrograms base), bioadhesive loading (2-30% w/w), and tablet volume (0.1-50 microliters).
- Claim 1 adds hard functional boundaries: minimal saliva response, minimal swallowing, and ≥55% oral transmucosal delivery.
- The patent extends coverage to SDA/syringe systems, ID and lockout dispensing controls, and user interface dose history transfer.
- Dependent claims lock in measurable and commercial-relevant parameters: specific doses (10 and 15 micrograms), adhesion force (0.03-0.18 N/cm² to porcine mucosa in vitro), disintegration time (10-30 minutes), and excipient choice (crosslinked sodium carboxymethylcellulose).
- For landscape management, the highest-risk design space is where a competitor’s tablet hits claim 1 performance thresholds while their delivery device matches the syringe SDA, dry-storage, and sublingual placement requirements.
FAQs
1) Does claim 1 require a specific saliva response mechanism (hydrogel vs eroding vs film)?
No. Claim 1 requires functional outcomes (minimal saliva response and minimal swallowing; ≥55% oral transmucosal delivery) but it does not force hydrogel vs eroding vs film. Those are handled in dependent claims 2-4.
2) What is the most enforceable pharmacokinetic boundary?
The clearest numeric boundary in the claim set is ≥55% of sufentanil delivery via the oral transmucosal route in claim 1.
3) Is the polymer system fixed?
Not in claim 1. Crosslinked sodium carboxymethylcellulose is explicitly recited in dependent claim 18, but competitors could use other bioadhesive/excipient systems and still face claim 1 exposure if other elements and performance thresholds match.
4) Do device claims create separate liability from the tablet?
Yes. Claims 7-8 and 21-25 create device/workflow exposure that can apply even if a tablet formulation is developed within similar performance bands.
5) Which dependent claims are most likely to align with commercial dose strengths?
Claims targeting 10 micrograms and 15 micrograms (claims 12-13) are direct alignment points when product strengths match those exact dose levels.
References
[1] USPTO Patent US 8,252,329, “Bioadhesive tablet for sublingual administration of sufentanil,” claims as provided in prompt.
